Filings/ROIV/10-Q

Source document

EDGAR
Loading document…
KPIsSections16
Headline metrics
Revenue — GREEN$1.4M-33.5% YoY
Net income — GREEN-$189.8M+15.0% YoY
Net margin — GREEN-13164.8%
Operating margin — RED-25380.9%
Red flags4 red1 orange
Liquidity3
RED
Negative operating cash flowoperating_cf_burn
The company is burning cash from operations — sustainability depends on financing.
RED
Net margin -13164.8%net_margin_sharply_negative
Net income margin below -5% — profitability materially negative vs revenue.
RED
Cash conversion (CFO/Rev) -18758.9%cash_conversion_weak
CFO/Revenue below 0 — operating model not generating cash despite revenue.
Dilution · capital1
RED
SBC/Revenue 5779.6%sbc_revenue_high
Stock-based compensation exceeds 25% of revenue — materially dilutive.
Concentration1
ORANGE
R&D/Revenue 14009.4%rd_intensity_high
R&D exceeds 40% of revenue — sustainable only if growth trajectory justifies the investment.
Income Statement
Income Statement
MetricValueFlag
Revenue$1.4MGREEN
Revenue (quarter)$1.4MGREEN
Operating Margin-25380.9%RED
Net Margin-13164.8%GREEN
Net Income-$189.8MGREEN
EPS (diluted)$-0.26GREEN
R&D % Revenue14009.4%GREEN
Balance Sheet
Balance Sheet
MetricValueFlag
Cash$1.25BGREEN
Broad Liquidity$3.84BGREEN
Current Ratio16.72GREEN
Total Assets$5.31BGREEN
Total Equity$4.23BGREEN
Cash Flow
Cash Flow
MetricValueFlag
Operating CF-$270.5MGREEN
Cash Conversion (CFO/Rev)-187.59GREEN
SBC % Revenue5779.6%GREEN
Free Cash Flow-$270.9MGREEN

Sections in this filing

Financial Statements (unaudited)

Item 1. Financial Statements (Unaudited). ROIVANT SCIENCES LTD. Condensed Consolidated Balance Sheets (unaudited, in thousands, except share and per share amounts) June 30, 2026 March 31, 2026 Assets Current assets: Cash and cash equivalents $ 1,248,456 $ 1,419,232 Marketable securities 2,593,626 2,872,601 Litigation settlement receivable 771,627 770,235 Other current assets 128,371 105,316 Total current assets 4,742,080 5,167,384 Property and equipment, net 11,320 11,986 Operating lease right-of-use assets 78,886 80,416 Investments measured at fair value 444,622 407,985 Other assets 29,585 40,916 Total assets $ 5,306,493 $ 5,708,687 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable $ 25,084 $ 18,002 Accrued expenses 168,740 205,823 Operating lease liabilities 12,384 11,147 Income tax payable 74,182 45,689 Other current liabilities 3,213 583 Total current liabilities 283,603 281,244 Operating lease liabilities, noncurrent 94,768 96,291 Income tax payable, noncurrent — 38,670 Other liabilities 6,253 70 Total liabilities 384,624 416,275 Commitments and contingencies (Note 10) Shareholders’ equity: Common shares, par value $ 0.0000000341740141 per share, 7,000,000,000 shares authorized and 722,668,062 and 720,352,386 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively — — Additional paid-in capital 5,130,926 5,024,826 Accumulated deficit ( 900,354 ) ( 501,814 ) Accumulated other comprehensive income 701 4,358 Shareholders’ equity attributable to Roivant Sciences Ltd. 4,231,273 4,527,370 Noncontrolling interests 690,596 765,042 Total shareholders’ equity 4,921,869 5,292,412 Total liabilities and shareholders’ equity $ 5,306,493 $ 5,708,687 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents ROIVANT SCIENCES LTD. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share amounts) Three Months Ended June 30, 2026 2025 Revenue $ 1,442 $ 2,170 Operating expenses: Cost of revenues 284 154 Research and development (includes $ 8,721 and $ 11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively) 202,016 152,919 General and administrative (includes $ 74,621 and $ 71,079 of share-based compensation expense for the three months ended June 30, 2026 and 202